AAD: Subcutaneous amlitelimab aids atopic dermatitis outcomes through week 24

Amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), is safe and effective, with potentially progressive efficacy over time, for patients with moderate-to-severe atopic dermatitis (AD),…

Continue Reading

News Source: medicalxpress.com